Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease

NCT07482917 is registered in ClinicalTrials.gov with Hospital de Granollers as lead sponsor.

NCT NCT07482917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07482917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease
Lead sponsor
Hospital de Granollers
Phase
Not applicable
Overall status
Recruiting
Start date
March 9, 2026
Completion date
March 1, 2028
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibrotic interstitial lung disease, idiopathic pulmonary fibrosis (ipf), interstitial lung disease (ild), interstitial lung disease due to connective tissue disease (disorder), suspected interstitial lung disease